This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zuplenz

Midatech Pharma PLC

Drug Names(s): Setofilm (EU), Ondansetron RapidFilm, ondansetron oral soluble film

Description: Zuplenz is an oral soluble form of ondansetron that utilizes MonoSol's PharmFilm drug delivery technology.

Deal Structure: Zuplenz was originally developed by APR Applied Pharma Research, MonoSol Rx, and Labtec.

MonoSol and Strativa
In June 2008, MonoSol Rx and Strativa announced that they have entered into an exclusive licensing agreement under which Strativa has acquired the U.S. commercialization rights to the thin film formulation of ondansetron from MonoSol Rx. Under terms of the agreement, MonoSol Rx will receive milestone payments prior to commercial launch and sales-based milestones that could total $23.5 million as well as payments for purchase of product supply and royalties on net sales.

In July 2011, MonoSol Rx announced that it made the strategic decision to reacquire the commercial rights to Zuplenz from Strativa.

BioAlliance and APR/Labtec
In August 2008, BioAlliance acquired the commercialization rights in Europe to the thin film formulation of ondansetron from APR/Labtec.

In June 2011, BioAlliance and APR Applied Pharma Research jointly decided to...See full deal structure in Biomedtracker

Partners: APR Applied Pharma Research SA Tesa SE MonoSol Rx Norgine B.V. Vestiq Pharmaceuticals R-Pharm Group


Zuplenz News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug